66931-56-4

Usage

Type of compound

Epoxide (cyclic ether with a three-membered ring)

Common uses

Building block in organic synthesis, production of chemicals and pharmaceuticals

Physical properties

Colorless liquid, slightly sweet odor

Handling precautions

Can be hazardous if not properly handled or stored

Upstream product

• 17849-38-6 2-Chlorobenzyl alcohol 
• 89-98-5 2-chloro-benzaldehyde 
• 106-89-8 epichlorohydrin 

Relevant academic research and scientific papers

1-(2-Chlorobenzyloxy)-3-[1,2,3]triazol-1-yl-propan-2-ol Derivatives: Synthesis, Characterization, and DFT-Based Descriptors Analysis

A novel series of 1-(2-chlorobenzyloxy)-3-[1,2,3]triazol-1-yl-propan-2-ol derivatives was designed and synthesized using copper catalyzed alkyne-azide cycloaddition in the key step. Theoretical investigation of molecular and electronic properties by means

Identification of a novel selective serotonin reuptake inhibitor by coupling monoamine transporter-based virtual screening and rational molecular hybridization

Ligand virtual screening (VS) using the vestibular binding pocket of a three-dimensional (3-D) monoamine transporter (MAT) computational model followed by in vitro pharmacology led to the identification of a human serotonin transporter (hSERT) inhibitor with modest affinity (hSERT Ki= 284 nM). Structural comparison of this VS-elucidated compound, denoted MI-17, to known SERT ligands led to the rational design and synthesis of DJLDU-3-79, a molecular hybrid of MI-17 and dual SERT/5-HT1Areceptor antagonist SSA-426. Relative to MI-17, DJLDU-3-79 displayed 7-fold improvement in hSERT binding affinity and a 3-fold increase in [3H]-serotonin uptake inhibition potency at hSERT-HEK cells. This hybrid compound displayed a hSERT:hDAT selectivity ratio of 50:1 and a hSERT:hNET (human norepinephrine transporter) ratio of >200:1. In mice, DJLDU-3-79 decreased immobility in the tail suspension test comparable to the SSRI fluvoxamine, suggesting that DJLDU-3-79 may possess antidepressant properties. This proof of concept study highlights MAT virtual screening as a powerful tool for identifying novel inhibitor chemotypes and chemical fragments for rational inhibitor design.

2-(arylalkyloxymethyl)morpholines and the central nervous system compositions

The present invention relates to new 2-(arylalkyloxymethyl)morpholine derivatives, the preparation thereof and their application as drugs which are useful in the treatment of disorders of the central nervous system. The 2-(arylalkyloxymethyl)morpholine derivatives according to the invention correspond to the general formula (I): STR1 in which: Ar denotes an aromatic group and more especially the following radicals: STR2 in the case where Ar denotes a phenyl radical and R denotes a hydrogen atom, an alkyl, alkoxy or halogen group, a trifluoromethyl radical, a nitro or amino group, a hydroxy group or an arylalkyloxy group.